EP3520811
Aðferðir til að auka fráblástursgetu asmasjúklings með því að nota benralísúmab
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
7.8.2014EP published:
30.12.2020EP application number:
19158446.5
EP translation filed:
16.3.2021Grant published:
15.4.2021EPO information:
European Patent Register
Max expiry date:
6.8.2034Expiry date:
6.8.2026Next due date:
31.8.2026
Title:
METHODS FOR INCREASING FORCED EXPIRATORY VOLUME IN ASTHMATICS USING BENRALIZUMAB
Timeline
Today
7.8.2014EP application
30.12.2020EP Publication
16.3.2021Translation submitted
15.4.2021Registration published
6.8.2026Expires
Owner
Name:
Astrazeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
WARD, ChristineAddress:
Gaithersburg, Maryland 20878, US
Name:
ROSKOS, LorinAddress:
Gaithersburg, Maryland 20878, US
Name:
WANG, BingAddress:
Gaithersburg, Maryland 20878, US
Name:
RAIBLE, DonaldAddress:
Berwyn, Pennsylvania 19312, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201361864948 PDate:
12.8.2013Country:
US
Classification
Categories:
A61K 39/00, A61K 39/395, G01N 33/48, A61P 11/06
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 29.7.2021
Expires: 6.8.2022
Payer: Árnason Faktor ehf.
Number: 9
Paid: 5.7.2022
Expires: 6.8.2023
Payer: Árnason Faktor ehf.
Number: 10
Paid: 11.7.2023
Expires: 6.8.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 9.7.2024
Expires: 6.8.2025
Payer: Árnason Faktor ehf.
Number: 12
Paid: 5.8.2025
Expires: 6.8.2026
Payer: Árnason Faktor ehf.